Kiora Pharmaceuticals (KPRX) Profit After Tax (2014 - 2026)

Kiora Pharmaceuticals (KPRX) has 13 years of Profit After Tax data on file, last reported at -$2.4 million in Q1 2026.

• Quarterly Profit After Tax fell 10.26% year-over-year to -$2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.0 million (up 9.44% YoY) and the FY2025 annual result came in at -$10.8 million, down 400.42% from the prior year.
• Profit After Tax grew to -$2.4 million in Q1 2026, from -$6.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $13.5 million in Q1 2024 to a low of -$6.5 million in Q4 2025.
• A 5-year average of -$2.1 million and a median of -$2.6 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax soared 819.99% — and 2025, when it sank 116.3%.
• Tracing KPRX's Profit After Tax over 5 years: stood at -$2.6 million in 2022, then increased by 12.57% to -$2.3 million in 2023, then tumbled by 90.91% to -$4.3 million in 2024, then tumbled by 50.51% to -$6.5 million in 2025, then jumped by 62.91% to -$2.4 million in 2026.
• The last three Profit After Tax figures came in at -$2.4 million (Q1 2026), -$6.5 million (Q4 2025), and $26806.0 (Q3 2025), per Business Quant data.